To include your compound in the COVID-19 Resource Center, submit it here.

BAY 43-9006: Phase II data

In a placebo-controlled Phase II trial in 202 evaluable patients with advanced kidney cancer, BAY 43-9006 met the primary endpoint of

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE